Mounjaro (Tirzepatide): Uses, Dosage, Storage and Global Availability

Introduction

Mounjaro is a prescription injectable medicine containing tirzepatide. It has attracted significant international attention because of its effects on blood-glucose control, appetite and body weight.

However, the approved uses of Mounjaro differ between countries. In the United States, Mounjaro is approved primarily for improving blood-glucose control in people with type 2 diabetes, while tirzepatide is marketed separately as Zepbound for chronic weight management. In the European Union and United Kingdom, Mounjaro is authorised for type 2 diabetes and for weight management in eligible adults.

This guide explains:

What Mounjaro is
How tirzepatide works
Approved Mounjaro uses
Available strengths
The usual Mounjaro dosage schedule
Storage and cold-chain requirements
Common side effects and important warnings
Mounjaro’s global regulatory availability

Medical disclaimer: This article is for general educational purposes and does not replace professional medical advice. Mounjaro is a prescription medicine and should be used only under the supervision of a qualified healthcare professional.

What Is Mounjaro?

Mounjaro is the brand name for tirzepatide, a medicine administered as a once-weekly injection under the skin.

Tirzepatide acts on two hormone-receptor pathways:

Glucose-dependent insulinotropic polypeptide, or GIP
Glucagon-like peptide-1, or GLP-1

These naturally occurring hormones are involved in regulating blood glucose, insulin release, appetite and food intake.

By activating both GIP and GLP-1 receptors, tirzepatide can:

Increase insulin secretion when glucose levels are elevated
Reduce inappropriate glucagon secretion
Improve insulin sensitivity
Slow gastric emptying, particularly after initial doses
Increase feelings of fullness
Reduce appetite and calorie intake

Mounjaro is not insulin. It works through hormone-receptor pathways that help the body respond more effectively to food and regulate blood glucose.

What Is Mounjaro Used For?

1. Type 2 diabetes management

Mounjaro is used alongside diet and physical activity to improve blood-glucose control in eligible people with type 2 diabetes.

In the United States, the current FDA prescribing information covers adults and paediatric patients aged ten years and older with type 2 diabetes mellitus. It is not indicated for the treatment of type 1 diabetes.

Depending on the patient’s condition and the relevant national label, Mounjaro may be used:

On its own when another medicine is unsuitable
With metformin
With other oral diabetes medicines
With insulin, under medical supervision

When Mounjaro is combined with insulin or an insulin-releasing medicine such as a sulfonylurea, the risk of low blood sugar may increase. A healthcare professional may therefore need to adjust the dose of the other medicine.

2. Weight management

Tirzepatide can reduce hunger, improve satiety and decrease food intake. As a result, weight reduction may occur during treatment.

The exact approved indication depends on the country.

In the United Kingdom, Mounjaro is authorised for weight management in adults who have:

A body mass index of 30 kg/m² or higher; or
A BMI from 27 kg/m² to below 30 kg/m² with at least one weight-related health condition

It is intended to be used together with a reduced-calorie diet and increased physical activity.

In the European Union, Mounjaro is also authorised for weight management in eligible adults with obesity or overweight and associated health problems.

In the United States, Mounjaro and Zepbound contain the same active ingredient, tirzepatide, but they have different approved branding and indications. Mounjaro is associated with type 2 diabetes treatment, while Zepbound is FDA-approved for chronic weight management in eligible patients.

Patients should therefore not assume that an indication approved in one country automatically applies in another.

Available Mounjaro Strengths

Mounjaro is commonly supplied in the following dose strengths:

Mounjaro 2.5 mg
Mounjaro 5 mg
Mounjaro 7.5 mg
Mounjaro 10 mg
Mounjaro 12.5 mg
Mounjaro 15 mg

Presentations differ by market. Depending on the country, tirzepatide may be supplied in:

Single-dose prefilled pens
Single-dose vials
Multi-dose KwikPens

For example, the United Kingdom has authorised a four-dose Mounjaro KwikPen containing four weekly doses, while Canadian listings include single-dose vials and KwikPen presentations.

Patients and healthcare providers must use the instructions supplied with the exact product presentation available in their market.

Mounjaro Dosage and Dose Escalation

Usual starting dose

The commonly recommended starting dosage is:

2.5 mg injected once weekly for four weeks.

The 2.5 mg dose is intended for treatment initiation. Under the US label, it is not intended to provide full glycaemic control.

Dose increase

After four weeks, the dose is commonly increased to:

5 mg once weekly.

When additional therapeutic benefit is required and the medicine is tolerated, the prescriber may increase the weekly dose in 2.5 mg increments.

The usual sequence is:

Weeks 1–4: 2.5 mg once weekly
Week 5 onward: 5 mg once weekly
Further increases when appropriate: 7.5 mg, 10 mg, 12.5 mg or 15 mg once weekly

Each increase is generally made only after the patient has remained on the current dose for at least four weeks. The maximum recommended weekly dose under major product labels is generally 15 mg.

This gradual escalation is intended to improve tolerability, particularly because nausea and other gastrointestinal effects can occur during treatment.

Important dosage warning

Patients must not increase their dosage without medical guidance. The correct maintenance dose depends on:

Treatment response
Blood-glucose levels
Treatment objective
Side effects
Other medications
Relevant national prescribing information
The patient’s overall medical condition

How Is Mounjaro Administered?

Mounjaro is injected under the skin once a week.

Recommended injection areas include:

Abdomen
Thigh
Upper arm

The injection may generally be administered with or without food. It should preferably be used on the same day every week. Injection sites should be rotated rather than repeatedly using the same spot.

Mounjaro must not be injected directly into a vein or muscle.

When Mounjaro and insulin are used during the same treatment period, they should be administered as separate injections. They should not be mixed in the same syringe.

What Happens If a Dose Is Missed?

Instructions may vary slightly by market, but the US prescribing information states that a missed dose may be taken within four days, or 96 hours, after the scheduled time.

When more than four days have passed, the missed dose should generally be skipped and the next dose administered on the regularly scheduled day.

Two doses should not be taken within three days, or 72 hours, of each other.

Patients should follow the leaflet supplied with their product and contact their healthcare provider when uncertain.

Mounjaro Storage Requirements

Maintaining the correct storage conditions is essential for protecting the quality and stability of tirzepatide.

Refrigerated storage

Unused Mounjaro products are generally stored in a refrigerator at:

2°C to 8°C, or 36°F to 46°F.

The medicine should remain in its original packaging when possible to protect it from light.

Do not freeze Mounjaro

Mounjaro must not be frozen.

A pen or vial that has been frozen should not be used, even if it later returns to room temperature.

The product should not be placed:

Directly beside a freezer compartment
Against refrigerator cooling elements
In dry ice
In unvalidated transport packaging where freezing may occur

Room-temperature storage

The permitted time outside refrigeration depends on the product presentation and country-specific label.

For example, the US label permits certain Mounjaro presentations to be stored at temperatures up to 30°C, or 86°F, for a limited period stated in the prescribing information. European and UK KwikPen presentations may have different in-use storage instructions.

Healthcare professionals, distributors and patients should never apply storage instructions from one presentation to another without checking the relevant package leaflet.

Protect the medicine from light and heat

Mounjaro should be protected from:

Direct sunlight
Excessive heat
Freezing temperatures
Uncontrolled temperature fluctuations
Damaged or wet packaging

The medicine should not be left for extended periods in a parked vehicle, near a window or inside checked airline baggage.

Cold-Chain Requirements for International Distribution

As a temperature-sensitive biological medicine, tirzepatide requires carefully controlled handling across the pharmaceutical supply chain.

Typical cold-chain controls may include:

Storage between 2°C and 8°C
Validated insulated packaging
Qualified refrigerants
Calibrated temperature-monitoring devices
Defined shipping duration
Protection against freezing
Temperature-excursion procedures
Batch and serial-number traceability
Import licences and local regulatory documentation
Verification of the destination country’s product registration

A temperature excursion does not automatically mean that a shipment must be discarded. However, the affected stock should generally be quarantined until the marketing-authorisation holder or another qualified authority evaluates the recorded temperature, exposure duration and applicable stability data.

Tab Exports supports international pharmaceutical supply activities with attention to documentation, compliant logistics and destination-market requirements. Availability remains subject to manufacturer authorisation, national registration, applicable pharmaceutical laws and a valid prescription where required.

Common Mounjaro Side Effects

The most frequently reported adverse effects are gastrointestinal.

Common Mounjaro side effects can include:

Nausea
Diarrhoea
Reduced appetite
Vomiting
Constipation
Indigestion
Abdominal discomfort or pain

These effects may be more noticeable when treatment begins or after the dosage is increased. Some patients find that symptoms decrease as their body adjusts, but persistent or severe symptoms require medical attention.

Important Warnings and Precautions

Thyroid C-cell tumour warning

The US prescribing information carries a boxed warning because tirzepatide caused thyroid C-cell tumours in laboratory rats. It is not known whether tirzepatide causes these tumours in humans.

Under the US label, Mounjaro is contraindicated in patients with:

A personal or family history of medullary thyroid carcinoma
Multiple endocrine neoplasia syndrome type 2

Patients should seek medical advice if they notice symptoms such as a neck lump, persistent hoarseness, difficulty swallowing or shortness of breath.

Warnings and contraindications are not worded identically in every jurisdiction, so local prescribing information must always be consulted.

Pancreatitis

Acute pancreatitis has been reported in patients receiving incretin-based treatments, including tirzepatide.

Severe and persistent abdominal pain, particularly when it radiates toward the back or is accompanied by vomiting, requires urgent medical assessment.

Low blood sugar

Mounjaro alone does not usually produce the same hypoglycaemia risk as insulin. However, the risk can rise when it is combined with:

Insulin
Sulfonylureas
Other medicines that significantly reduce blood glucose

Possible symptoms include sweating, shakiness, hunger, dizziness, confusion, weakness or a rapid heartbeat.

Dehydration and kidney problems

Vomiting, diarrhoea and reduced fluid intake may cause dehydration. In severe cases, dehydration can contribute to acute kidney injury.

Patients experiencing prolonged gastrointestinal symptoms should contact a healthcare professional and maintain an appropriate fluid intake unless they have been given medical fluid restrictions.

Gallbladder problems

Tirzepatide treatment may be associated with gallbladder-related conditions such as gallstones or inflammation of the gallbladder.

Symptoms requiring medical evaluation can include:

Severe upper abdominal pain
Fever
Yellowing of the skin or eyes
Pale stools
Persistent nausea or vomiting

Severe gastrointestinal disease

Because tirzepatide delays gastric emptying, it may not be appropriate for certain patients with serious gastrointestinal disorders, including severe gastroparesis. The US prescribing information states that it is not recommended in patients with severe gastroparesis.

Pregnancy

Weight loss is not recommended during pregnancy. Patients who are pregnant, planning pregnancy or become pregnant during treatment should promptly consult their healthcare provider.

Tirzepatide may also reduce the effectiveness of oral hormonal contraceptives for a period after treatment initiation and after each dosage increase because it delays gastric emptying. Patients should follow the contraceptive advice in the applicable prescribing information.

Who Should Not Use Mounjaro?

Mounjaro may not be suitable for everyone.

Medical assessment is especially important for people with:

A history of severe allergy to tirzepatide or its ingredients
A personal or family history of medullary thyroid carcinoma, where the US contraindication applies
Multiple endocrine neoplasia syndrome type 2
Previous pancreatitis
Severe gastroparesis or another serious gastrointestinal disorder
Gallbladder disease
Diabetic retinopathy
Pregnancy or plans to become pregnant
Concurrent insulin or sulfonylurea treatment

Patients should provide their prescriber with a complete list of medicines, supplements and medical conditions before starting treatment.

Mounjaro Global Availability

Mounjaro’s approval status, indication, presentation, supply position and prescribing rules vary between countries.

United States

The FDA approved Mounjaro in 2022 for improving glycaemic control in adults with type 2 diabetes alongside diet and exercise. The current US label also covers paediatric patients aged ten years and older.

For chronic weight management, tirzepatide is marketed in the United States under the brand name Zepbound, not Mounjaro.

United Kingdom

The MHRA has authorised Mounjaro for type 2 diabetes and weight management in eligible adults.

The UK has also approved a four-dose Mounjaro KwikPen that provides four once-weekly doses.

European Union

Mounjaro has marketing authorisation in the European Union for type 2 diabetes and weight management in eligible patients.

The European Commission also authorised a multi-dose KwikPen presentation in 2024.

India

CDSCO committee records state that tirzepatide prefilled pens were approved in India in January 2024 for improving glycaemic control in adults with type 2 diabetes, subject to conditions that included a Phase IV clinical trial.

Current commercial availability, approved presentations and permissible indications should be checked against the latest CDSCO records and manufacturer information before procurement or supply.

Canada

Health Canada’s Drug Product Database includes Mounjaro and Mounjaro KwikPen prescription products containing tirzepatide in different presentations and strengths.

Brazil

Brazil’s health regulator, Anvisa, states that Mounjaro is registered for type 2 diabetes and has also received an additional indication related to weight management under defined eligibility conditions.

Other international markets

Tirzepatide has also received approvals in several additional markets. Nevertheless, approval does not always mean every dosage, pack type or indication is immediately commercially available.

Before importing or supplying Mounjaro, buyers should verify:

National marketing authorisation
Approved indication
Licensed importer or distributor requirements
Current manufacturer supply
Pack presentation
Labelling language
Prescription status
Cold-chain capability
Import permit requirements
Product authenticity and traceability

How to Identify Genuine Mounjaro

Growing demand for GLP-1 and related medicines has increased the risk of falsified, unauthorised and incorrectly stored products.

Patients and healthcare buyers should obtain Mounjaro only through legal and authorised supply channels.

Check the following:

The supplier holds the necessary pharmaceutical licences
The product has a traceable batch number
The expiry date is readable and valid
Packaging is sealed and undamaged
The correct local-language leaflet is included
Storage records are available
Serialisation or anti-counterfeit features are intact
The product matches the authorised presentation for the destination market

Health Canada has specifically warned consumers about counterfeit or unauthorised GLP-1 products and advises obtaining prescription medicines only from licensed pharmacies.

Products sold without a prescription, through unverified social-media accounts or with claims such as “research use only” may be unsafe, counterfeit or illegal.

Mounjaro Procurement Considerations for Importers and Distributors

Pharmaceutical importers evaluating tirzepatide products should complete regulatory and supplier due diligence before placing an order.

Key documents may include:

Wholesale drug licence
Manufacturing authorisation
Good Manufacturing Practice certificate
Certificate of Pharmaceutical Product
Certificate of Analysis
Commercial invoice
Packing list
Batch-release documentation
Temperature records
Certificate of Origin
Import permit
Product registration or marketing authorisation
Pharmacovigilance arrangements

The exact documentation depends on the importing country, product category, shipment size and local health-authority requirements.

Tab Exports works with international pharmaceutical buyers to support product enquiries, export documentation and temperature-controlled supply planning, subject to applicable laws, prescriptions, registrations and manufacturer-authorised distribution arrangements.

Frequently Asked Questions About Mounjaro

Is Mounjaro the same as tirzepatide?

Mounjaro is a brand name for a medicine containing tirzepatide. Tirzepatide is the active pharmaceutical ingredient.

Is Mounjaro insulin?

No. Mounjaro is not insulin. It activates GIP and GLP-1 receptors involved in glucose regulation and appetite.

How often is Mounjaro injected?

Mounjaro is normally injected once a week on the same day each week.

What is the starting dose of Mounjaro?

The commonly recommended starting dose is 2.5 mg once weekly for four weeks. The dosage is then generally increased to 5 mg once weekly under medical supervision.

What is the maximum Mounjaro dose?

The maximum recommended dose under major prescribing labels is generally 15 mg once weekly. A prescriber determines whether dose escalation is appropriate.

Can Mounjaro be used for weight loss?

Tirzepatide can support weight reduction, but the approved brand and indication depend on the country. Mounjaro is authorised for weight management in markets including the UK and EU. In the United States, tirzepatide is approved for chronic weight management under the Zepbound brand.

Does Mounjaro need refrigeration?

Yes. Unused Mounjaro is generally stored between 2°C and 8°C. It must not be frozen. Exact room-temperature and in-use limits depend on the presentation and country-specific label.

Can Mounjaro be transported internationally?

It may be transported internationally only when pharmaceutical, customs, prescription, import and cold-chain requirements are satisfied. The product must be authorised for the destination market, and its temperature must remain within validated limits.

Can Mounjaro be purchased without a prescription?

Mounjaro is a prescription medicine in major regulated markets. Offers to sell it without appropriate medical or pharmaceutical controls should be treated cautiously.

Is Mounjaro available everywhere?

No. Its approval, indication, dosage presentation and commercial availability vary by country. Buyers should verify the latest information with the local medicines regulator and authorised supplier.